Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204562 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5208016 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5208892 | 0.84 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL5204929 | 0.84 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL7487002 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7488169 | 0.83 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL5207849 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4575651 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5207033 | 0.81 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL7493186 | 0.81 | PTGS2 (0.72) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863891-B1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2002-12-11 | — | — | EP | claimed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | claimed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | claimed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | claimed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1259235-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-6927293-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-08-09 | — | — | US | disclosed |
| WO-2001062251-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6169188-B1 | TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES | MERCK FROSST CANADA & CO. (CA) | 2001-01-02 | — | — | US | disclosed |
| US-6057319-A | CYCLOOXYGENASE-2 INHIBITORS; NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2000-05-02 | — | — | US | disclosed |
| US-6020343-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 2000-02-01 | — | — | US | disclosed |
| US-5981576-A | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors | MERCK FROSST CANADA, INC. (CA) | 1999-11-09 | — | — | US | disclosed |
| EP-0863891-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-09-16 | — | — | EP | disclosed |
| US-5698584-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-12-16 | — | — | US | disclosed |
| WO-1997014691-A1 | (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES AS COX-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PTGS2 14/4885PTGS1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.